MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021

MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021

Source: 
Xconomy
snippet: 

An experimental MyoKardia drug developed to treat an inherited cardiovascular condition that restricts blood flow is showing it can improve on the symptoms of this condition as well as the heart’s ability to function.